linjc16/ctgov huggingface dataset:
The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Injured Soldiers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to define the reliability and accuracy of Near Infrared Spectroscopy (NIRS) in the detection of intra-compartmental tissue perfusion in injured and noninjured extremities over time. The investigators hypothesize that this technology, combined with vital signs, intracompartmental pressures and clinical examinations, will be useful in diagnosing acute compartment syndrome (ACS), monitoring patients at risk for ACS, and evaluating the adequacy of fasciotomy in patients treated for ACS.

Official Title
-----------------
The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Injured Soldiers

Conditions
-----------------
Acute Compartment Syndrome

Intervention / Treatment
-----------------
* Device: near-infrared spectroscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-65 years old male or female active duty servicemen who have been evacuated from OIF or OEF through LRMC Exclusion Criteria: patients not willing to provide consent patients in whom application of NIRS monitoring is viewed as an impediment to casualty care

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stable controls<br>Uninjured soldiers to provide normative data for stable physiological status | Device: near-infrared spectroscopy<br>* Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.<br>|
| Critical controls<br>Critically injured soldiers with no lower extremity traumatic injuries (excepting skin abrasions and small/superficial fragmentation wounds) to provide normative data for the shock physiological status. | Device: near-infrared spectroscopy<br>* Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.<br>|
| Lower extremity trauma<br>Soldiers with severe traumatic lower extremity injuries in stable and shock physiologic status. This is the investigational cohort. | Device: near-infrared spectroscopy<br>* Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NIRS values in various physiologic states (stable control, critically injured control, lower extremity injury) |  | 24-48 hours from hospital admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
near infrared spectroscopy, lower extremity injury
Study of Antenatal Thyrotropin-Releasing Hormone in Women in Premature Labor to Prevent Lung Disease in Preterm Infants

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Assess the efficacy and safety of antenatal administration of thyrotropin-releasing hormone to women in premature labor to improve pulmonary outcomes in preterm infants.

Detailed Description
-----------------
PROTOCOL OUTLINE: This is a randomized, double blind, multicenter study. Patients are randomized to receive antenatal thyrotropin-releasing hormone or placebo. Patients receive thyrotropin-releasing hormone or placebo intravenously over 20 minutes every 8 hours for 4 doses. Infants are assessed for survival and chronic lung disease until day 28 after birth, and again at 36 postmenstrual weeks.

Conditions
-----------------
Respiratory Distress Syndrome

Intervention / Treatment
-----------------
* Drug: thyrotropin-releasing hormone


Participation Criteria
=================
Eligibility Criteria
-----------------
Pregnant women in active labor with 24-29 weeks gestation Not eligible if any of the following is present: Bleeding Infection Hypertension (greater than 140/90 mmHg) Fetus with hydrops or life-threatening anomalies One dead fetus in multiple pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 36 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: thyrotropin-releasing hormone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiovascular and respiratory diseases, neonatal disorders, rare disease, respiratory distress syndrome
Impact of Air Quality on Exacerbations of COPD in the Somme

Study Overview
=================
Brief Summary
-----------------
All COPD patients with a diagnosis of acute exacerbation in emergency room in University Hospital of Amiens-Picardie between 01/01/2017 and 31/12/2017. The investigator will collect for each patient the home address and the work address. The duration of 1 year was chosen to take into account seasonal variations. In parallel, a daily report of the rate of ozone, particles (PM2.5 and PM10), dioxide nitrogen but also odours and pollens will be done by ATMO Picardie.

Official Title
-----------------
Impact of Air Quality on Exacerbations of COPD in the Somme

Conditions
-----------------
Acute Exacerbation Copd

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All COPD patients with a diagnosis of acute exacerbation of COPD in the emergency room. The definition of COPD and acute exacerbation are the official definition of the Société de Pneumologie en Langue Française. Exclusion Criteria: no exclusion criteria
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| exacerbation rate : variable to be explicated with explicative variable : ozone, particles, dioxide nitrogen, but also pollens corresponding to each patient home address for period of exacerbation | exacerbation rate : variable to be explicated with explicative variable : ozone, particles, dioxide nitrogen, but also pollens corresponding to each patient home address for period of exacerbation | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pollution, ozone, Copd, particles
Observational Study of Nelarabine in Children and Young Adults

Study Overview
=================
Brief Summary
-----------------
This international, multicentre, single arm, phase IV study will assess the safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia (T-ALL) or lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. It is a post-authorisation safety study (PASS) conducted for the purpose of confirming the safety profile and the clinical benefit of nelarabine under licensed conditions of use. The study is observational, non-interventional, and will include approximately 40 children and young adults (up to 21 years of age).

Official Title
-----------------
A Multicentre, Single Arm, Observational Phase IV Study to Assess the Safety and Efficacy of Nelarabine in Children and Young Adults (up to 21 Years of Age) With Relapsed or Refractory T-Lineage Acute Lymphoblastic Leukaemia or Lymphoblastic Lymphoma

Conditions
-----------------
Leukaemia, Lymphoblastic, Acute

Intervention / Treatment
-----------------
* Drug: nelarabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≤ 21 years of age Relapsed or refractory T-lineage acute lymphoblastic leukaemia (T-ALL) or lymphoblastic lymphoma (T-LBL) Prior treatment with at least two chemotherapy regimens Selected for treatment with nelarabine Exclusion Criteria: Known hypersensitivity to the active substance. Women of childbearing potential who are unable or unwilling to use adequate contraceptive measures Males with partners of child bearing potential who are not willing to use condoms or abstinence Patients with persistent neurological toxicity (CTC grade > = grade 2) Adolescents (aged 16 years and over) and adults for whom the physician prescribes the 1500mg/m2 dose of nelarabine.

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Nelarabine<br>nelarabine 650mg/m2 IV daily for 5 days. repeat every 21 days. | Drug: nelarabine<br>* Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurological adverse events |  | Up to one year after treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Other adverse events |  | Up to one year after treatment | 
| clinical response rate and survival |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
T-ALL, Safety, Post Authorisation Safety Study, T-LBL, Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia
ULTRA Study for Pacemaker Patients

Study Overview
=================
Brief Summary
-----------------
The ULTRA study will assess the difference in average ventricular voltage output for pacemaker patients randomized to Automatic Capture feature ON versus patients randomized to Automatic Capture feature OFF.

Official Title
-----------------
Ventricular Automatic Capture Assessment Study

Conditions
-----------------
Bradycardia

Intervention / Treatment
-----------------
* Device: Pacemaker with Automatic Capture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who meet current INSIGNIA® Ultra pacemaker indications Patients who will be programmed to a pacing mode of DDD, DDDR, VVI, VVIR, or VDD at the time of implant Patients who sign and date a Patient Informed Consent form at or prior to the implant visit Patients who remain in the clinical care of the enrolling physician in approved centers Exclusion Criteria: Patients who will receive a single chamber device with an atrial lead only Patients who have chronic leads with a ventricular threshold of more than 4.0 V Patients whose life expectancy is less than 12 months Patients who are expected to receive a heart transplant during the duration of the study Patients who have or who are likely to receive a tricuspid valve prosthesis Patients who are currently enrolled in another investigational study that would directly impact the treatment or outcome of the ULTRA study. Patients who are younger than 18 years of age Patients who are pregnant Patients who are mentally incompetent and cannot sign a Patient Informed Consent form or comply with the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Pacemaker with Automatic Capture|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average ventricular voltage output over time for patients randomized to Automatic Capture feature ON versus patients randomized to Automatic Capture feature OFF |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare automatic and manual threshold tests |  |  | 
| Project device longevity |  |  |
H - Test Usage in Identification of Sexual Orientation Among People.

Study Overview
=================
Brief Summary
-----------------
Using of H - test in identifying the sexual behavior of the human.

Detailed Description
-----------------
The test using videos and in the same time watching the vital signs of the participant to identify any changes in them align with the vides. These videos contain +18 contents that can excite them and make them sexually active. So we can determine with type of vides that more excited to the human and select his or her sexual behavior type.

Official Title
-----------------
Using H - Test to Identify the Sexual Orientation and Applying the Test in Medical and Forensic Fields

Conditions
-----------------
Sexual Behavior, Sexual Orientation Conflict Disorder, Sexual Arousal Disorder, Sexual Orientation, Sexual; Orientation, Relationship Disorder

Intervention / Treatment
-----------------
* Diagnostic Test: H - Test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All the people can be included Exclusion Criteria: Have a psychological disorder Have a sexual disorder

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Hashim Talib Hashim<br>It is a video with +18 different contents to know the effect of much video than the others. | Diagnostic Test: H - Test<br>* Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.<br>* Other names: Sexual health test;|
| Experimental: Mustafa Ahmed Ramadhan<br>Is is an assessment of the vital signs among the participants and the change with the showing of videos. | Diagnostic Test: H - Test<br>* Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.<br>* Other names: Sexual health test;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| An observatory stimulation test of sexual orientation (Straight, gay, lesbian, bisexual) by using videos stimulation | Using the test to arouse the sexual state among the participants by using sexual videos either for gays or straights, that can stimulate them sexually while monitoring their vitals to see the changes that can occur with each videos and the most effective video will be considered as a sufficient stimulus. | 1 week |
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
This trial will evaluate the feasibility, toxicity, and efficacy of docetaxel/estramustine, as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local therapy.

Detailed Description
-----------------
Upon determination of eligibility, patients will receive: Docetaxel + Estramustine

Official Title
-----------------
Adjuvant Chemotherapy (Docetaxel and Estramustine Phosphate) for High Risk Localized Prostate Cancer

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Drug: Docetaxel
* Drug: Estramustine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be included in this study, you must meet the following criteria: Histologically confirmed adenocarcinoma of the prostate Clinically or surgically staged localized disease, stage I-III. Prior surgical resection or radiation therapy with curative intent No clinical evidence of residual disease Gleason's combined score > 7. Age > 18 years. No prior chemotherapy for prostate cancer. No previous androgen deprivation therapy for prostate cancer Able to perform activities of daily living with minimal assistance Adequate bone marrow, liver and kidney function Voluntarily provide written informed consent. Exclusion Criteria: You cannot participate in this study if any of the following apply to you: History of prior malignancy in the past five years History of significant heart disease within the previous 6 months Cerebral vascular accident (CVA) or stroke within the previous 6 months. Moderate or severe peripheral neuropathy Previous therapy with other injectable radioisotopes. Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Docetaxel|nan|
|Drug: Estramustine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response Rate |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of recurrence |  |  | 
| Toxicity |  |  |
Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control Study

Study Overview
=================
Brief Summary
-----------------
COVID-19 is currently one of the serious public health challenges worldwide, and there is a great need to develop effective treatments. Paxlovid is a Pfizer-developed oral new drug for the treatment of COVID-19. Paxlovid, which is used to treat adult patients with mild to moderate COVID-19 who have high-risk factors for progression to severe disease, was conditionally approved for marketing in the United States and China in December 2021 and February 2022, respectively. Clinical trials have shown that this drug can significantly reduce the progression from mild to severe disease and the rate of hospitalization and mortality. However, due to the limitations of clinical trials in the subject selection, there is still insufficient knowledge about the efficacy and safety of Paxlovid in a real-world population. Relevant studies on this drug in real-world people, especially in Chinese populations, have not been reported. Therefore, this study was designed to investigate the efficacy and safety of Paxlovid on sufferers of COVID-19 through a retrospective, real-world analysis.

Official Title
-----------------
Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control Study

Conditions
-----------------
COVID-19 Pneumonia

Intervention / Treatment
-----------------
* Drug: standard-of-care plus Paxlovid
* Drug: standard-of-care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with confirmed COVID-19 who had taken more than one dose of Paxlovid. Exclusion Criteria: Age < 18 years-old; Pregnancy; Data missing > 20%.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: standard-of-care<br> | Drug: standard-of-care<br>* standard-of-care<br>|
| Experimental: standard-of-care plus Paxlovid<br> | Drug: standard-of-care plus Paxlovid<br>* standard-of-care plus Paxlovid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 28-day mortality | the mortality of the subjects within 28 days since the diagnosis of COVID-19 | 28 days since the diagnosis of COVID-19 |